Editors’ Choice 2015 papers in Thrombosis and Haemostasis

• References

• 1 Husted S, de Caterina R, Andreotti F. et al. ESC Working Group on Thrombosis Task Force on Anticoagulants in Heart Disease.. Non-vitamin K antagonist oral anticoagulants (NOACs): No longer new or novel. Thromb Haemost 2014; 111: 781-782.
• 2 Dickneite G, Hoffman M. Reversing the new oral anticoagulants with prothrombin complex concentrates (PCCs): what is the evidence?. Thromb Haemost 2014; 111: 189-198.
• 3 Schulman S. New oral anticoagulant agents - general features and outcomes in subsets of patients. Thromb Haemost 2014; 111: 575-582.
• 4 Chiang CE, Wang KL, Lip GY. Stroke prevention in atrial fibrillation: an Asian perspective. Thromb Haemost 2014; 111: 789-797.
• 5 Lowres N, Neubeck L, Salkeld G. et al. Feasibility and cost-effectiveness of stroke prevention through community screening for atrial fibrillation using iPhone ECG in pharmacies. The SEARCH-AF study. Thromb Haemost 2014; 111: 1167-1176.
• 6 Lahaye S, Regpala S, Lacombe S. et al. Evaluation of patients’ attitudes towards stroke prevention and bleeding risk in atrial fibrillation. Thromb Haemost 2014; 111: 465-473.
• 7 Skjøth F, Larsen TB, Rasmussen LH. et al. Efficacy and safety of edoxaban in comparison with dabigatran, rivaroxaban and apixaban for stroke prevention in atrial fibrillation. An indirect comparison analysis. Thromb Haemost 2014; 111: 981-988.
• 8 Hylek EM, Ko D, Cove CL. Gaps in translation from trials to practice: non-vitamin K antagonist oral anticoagulants (NOACs) for stroke prevention in atrial fibrillation. Thromb Haemost 2014; 111: 783-788.
• 9 Chan NC, Paikin JS, Hirsh J. et al. New oral anticoagulants for stroke prevention in atrial fibrillation: impact of study design, double counting and unexpected findings on interpretation of study results and conclusions. Thromb Haemost 2014; 111: 798-807.
• 10 Hankey GJ. Unanswered questions and research priorities to optimise stroke prevention in atrial fibrillation with the new oral anticoagulants. Thromb Haemost 2014; 111: 808-816.
• 11 Lei X, Reheman A, Hou Y. et al. Anfibatide, a novel GPIb complex antagonist, inhibits platelet adhesion and thrombus formation in vitro and in vivo in murine models of thrombosis. Thromb Haemost 2014; 111: 279-289.
• 12 Geddings JE, Mackman N. New players in haemostasis and thrombosis. Thromb Haemost 2014; 111: 570-574.
• 13 de Stoppelaar SF, van ’t Veer C, van der Poll T. The role of platelets in sepsis. Thromb Haemost 2014; 112: 666-677.
• 14 Nencioni A, da Silva RF, Fraga-Silva RA. et al. Nicotinamide phosphoribosyltransferase inhibition reduces intraplaque CXCL1 production and associated neutrophil infiltration in atherosclerotic mice. Thromb Haemost 2014; 111: 308-322.
• 15 Badrnya S, Baumgartner R, Assinger A. Smoking alters circulating plasma microvesicle pattern and microRNA signatures. Thromb Haemost 2014; 112: 128-136.
• 16 Freynhofer MK, Gruber SC, Grove EL. et al. Anti-platelet drugs in patients with enhanced platelet turnover: biomarkers versus platelet function testing. Thromb Haemost 2015; 114: 459-468.
• 17 Cabrera-Fuentes HA, Lopez ML, McCurdy S. et al. Regulation of monocyte/macrophage polarisation by extracellular RNA. Thromb Haemost 2015; 113: 473-481.
• 18 Mannucci PM, Franchini M. Classic thrombophilic gene variants. Thromb Haemost 2015; 114: 885-889.
• 19 Riva N, Donadini MP, Ageno W. Epidemiology and pathophysiology of venous thromboembolism: similarities with atherothrombosis and the role of inflammation. Thromb Haemost 2015; 113: 1176-1183.
• 20 Santilli F, Pignatelli P, Violi F. et al. Aspirin for primary prevention in diabetes mellitus: from the calculation of cardiovascular risk and risk/benefit profile to personalised treatment. Thromb Haemost 2015; 114: 876-882.
• 21 Siller-Matula JM, Trenk D, Schrör K. et al. European Platelet Academy.. How to improve the concept of individualised antiplatelet therapy with P2Y12 receptor inhibitors--is an algorithm the answer?. Thromb Haemost 2015; 113: 37-52.
• 22 Spek CA, Versteeg HH, Borensztajn KS. Anticoagulant therapy of cancer patients: Will patient selection increase overall survival?. Thromb Haemost 2015; 114: 530-536.
• 23 Karnes JH, Cronin RM, Rollin J. et al. A genome-wide association study of heparin-induced thrombocytopenia using an electronic medical record. Thromb Haemost 2015; 113: 772-781.
• 24 Metzger JM, Tadin-Strapps M, Thankappan A. et al. Titrating haemophilia B phenotypes using siRNA strategy: evidence that antithrombotic activity is separated from bleeding liability. Thromb Haemost 2015; 113: 1300-1311.
• 25 Aradi D, Collet JP, Mair J. et al. Study Group on Biomarkers in Cardiology of the Acute Cardiovascular Care Association of the European Society of Cardiology; Working Group on Thrombosis of the European Society of Cardiology.. Platelet function testing in acute cardiac care - is there a role for prediction or prevention of stent thrombosis and bleeding?. Thromb Haemost 2015; 113: 221-230.
• 26 Corduan A, Plé H, Laffont B. et al. Dissociation of SERPINE1 mRNA from the translational repressor proteins Ago2 and TIA-1 upon platelet activation. Thromb Haemost 2015; 113: 1046-1059.
• 27 Rheinlaender J, Vogel S, Seifert J. et al. Imaging the elastic modulus of human platelets during thrombin-induced activation using scanning ion conductance microscopy. Thromb Haemost 2015; 113: 305-311.
• 28 Nordling S, Hong J, Fromell K, Edin F, Brännström J, Larsson R, Nilsson B, Magnusson PU. Vascular repair utilising immobilised heparin conjugate for protection against early activation of inflammation and coagulation. Thromb Haemost 2015; 113: 1312-1322.
• 29 Daniel JM, Reich F, Dutzmann J. et al. Cleaved high-molecular-weight kininogen inhibits neointima formation following vascular injury. Thromb Haemost 2015; 114: 603-613.
• 30 Radecke CE, Warrick AE, Singh GD. et al. Coronary artery endothelial cells and microparticles increase expression of VCAM-1 in myocardial infarction. Thromb Haemost 2015; 113: 605-616.
• 31 Mego M, Zuo Z, Gao H. et al. Circulating tumour cells are linked to plasma D-dimer levels in patients with metastatic breast cancer. Thromb Haemost 2015; 113: 593-598.
• 32 Smadja DM, Levy M, Huang L. et al. Treprostinil indirectly regulates endothelial colony forming cell angiogenic properties by increasing VEGF-A produced by mesenchymal stem cells. Thromb Haemost 2015; 114: 735-747.
• 33 Du J, Wichapong K, Hackeng KM. et al. Molecular simulation studies of human coagulation factor VIII C domain-mediated membrane binding. Thromb Haemost 2015; 113: 373-384.
• 34 Cirillo P, Ziviello F, Pellegrino G. et al. The adipokine apelin-13 induces expression of prothrombotic tissue factor. Thromb Haemost 2015; 113: 363-372.
• 35 Rodríguez-Calvo R, Ferrán B, Alonso J. et al. NR4A receptors up-regulate the antiproteinase alpha-2 macroglobulin (A2M) and modulate MMP-2 and MMP-9 in vascular smooth muscle cells. Thromb Haemost 2015; 113: 1323-1334.
• 36 Burillo E, Lindholt JS, Molina-Sánchez P. et al. ApoA-I/HDL-C levels are inversely associated with abdominal aortic aneurysm progression. Thromb Haemost 2015; 113: 1335-1346.
• 37 Bjerregaard N, Bøtkjær KA, Helsen N. et al. Tissue-type plasminogen activator-binding RNA aptamers inhibiting low-density lipoprotein receptor family-mediated internalisation. Thromb Haemost 2015; 114: 139-149.
• 38 Li Z, Sun X, Guo S. et al. Rapid stabilisation of atherosclerotic plaque with 5-aminolevulinic acid-mediated sonodynamic therapy. Thromb Haemost 2015; 114: 793-803.
• 39 Lip GY, Skjøth F, Nielsen PB. et al. Non-valvular atrial fibrillation patients with none or one additional risk factor of the CHA2DS2-VASc score. A comprehensive net clinical benefit analysis for warfarin, aspirin, or no therapy. Thromb Haemost 2015; 114: 826-834.
• 40 Lip GY, Clemens A, Noack H. et al. Patient outcomes using the European label for dabigatran. A post-hoc analysis from the RE-LY database. Thromb Haemost 2014; 111: 933-942.
• 41 Seeger JD, Bykov K, Bartels DB. et al. Safety and effectiveness of dabigatran and warfarin in routine care of patients with atrial fibrillation. Thromb Haemost. 2015 Oct 8; Epub ahead of print.
• 42 Villines TC, Schnee J, Fraeman K. et al. A comparison of the safety and effectiveness of dabigatran and warfarin in non-valvular atrial fibrillation patients in a large healthcare system. Thromb Haemost. 2015 Oct 08. Epub ahead of print.
• 43 Avgil-Tsadok M, Jackevicius CA, Essebag V. et al. Dabigatran use in elderly patients with atrial fibrillation. Thromb Haemost. 2015 Sep 10. Epub ahead of print.
• 44 Pezzini A, Grassi M, Lodigiani C. et al. Italian Project on Stroke in Young Adults (IPSYS) Investigators.. Determinants of premature familial arterial thrombosis in patients with juvenile ischaemic stroke. The Italian Project on Stroke in Young Adults (IPSYS). Thromb Haemost 2015; 113: 641-648.
• 45 Reiner MF, Martinod K, Stivala S. et al. Dietary omega-3 alpha-linolenic acid does not prevent venous thrombosis in mice. Thromb Haemost 2015; 113: 177-184.
• 46 Lappegård J, Ellingsen TS, Vik A. et al. Red cell distribution width and carotid atherosclerosis progression. The Tromsø Study. Thromb Haemost 2015; 113: 649-654.
• 47 Pulakazhi Venu VK, Uboldi P, Dhyani A. et al. Fibronectin extra domain A stabilises atherosclerotic plaques in apolipoprotein E and in LDL-receptor-deficient mice. Thromb Haemost 2015; 114: 186-197.
• 48 Montecucco F, Braunersreuther V, Burger F. et al. Anti-apoA-1 auto-antibodies increase mouse atherosclerotic plaque vulnerability, myocardial necrosis and mortality triggering TLR2 and TLR4. Thromb Haemost 2015; 114: 410-422.